{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:16:53Z","timestamp":1787008613163,"version":"build-2736575974"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MCT-44154"],"award-info":[{"award-number":["MCT-44154"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MCT-94831"],"award-info":[{"award-number":["MCT-94831"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The safety and efficacy of rifampin among people living with human immunodeficiency virus (PLHIV) or other health conditions is uncertain. We assessed completion, safety, and efficacy of 4 months of rifampin vs 9 months of isoniazid among PLHIV or other health conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted post hoc analysis of 2 randomized trials that included 6859 adult participants with Mycobacterium tuberculosis infection. Participants were randomized 1:1 to 10 mg\/kg\/d rifampin or 5 mg\/kg\/d isoniazid. We report completion, drug-related adverse events (AE), and active tuberculosis incidence among people living with HIV; with renal failure or receiving immunosuppressants; using drugs or with hepatitis; with diabetes mellitus; consuming &amp;gt;1 alcoholic drink per week or current\/former smokers; and with no health condition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 270 (3.9%) people were living with HIV (135 receiving antiretroviral therapy), 2012 (29.3%) had another health condition, and 4577 (66.8%) had no condition. Rifampin was more often or similarly completed to isoniazid in all populations. AEs were less common with rifampin than isoniazid among PLHIV (risk difference, \u22122.1%; 95% confidence interval [CI], \u22125.9 to 1.6). This was consistent for others except people with renal failure or on immunosuppressants (2.1%; 95% CI, \u22127.2 to 11.3). Tuberculosis incidence was similar among people receiving rifampin or isoniazid. Among participants receiving rifampin living with HIV, incidence was comparable to those with no health condition (rate difference, 4.1 per 1000 person-years; 95% CI, \u22126.4 to 14.7).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Rifampin appears to be safe and as effective as isoniazid across many populations with health conditions, including HIV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trials Registration<\/jats:title>\n                    <jats:p>NCT00170209; NCT00931736.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaa1169","type":"journal-article","created":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T15:29:19Z","timestamp":1596641359000},"page":"e3545-e3554","source":"Crossref","is-referenced-by-count":21,"title":["Safety and Efficacy of Rifampin or Isoniazid Among People With\n                    <i>Mycobacterium tuberculosis<\/i>\n                    Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials"],"prefix":"10.1093","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2341-2166","authenticated-orcid":false,"given":"Jonathon R","family":"Campbell","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada"},{"name":"McGill International TB Centre, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamdan","family":"Al-Jahdali","sequence":"additional","affiliation":[{"name":"Department of Medicine, King Saud University for Health Sciences, King Abdulaziz Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boubacar","family":"Bah","sequence":"additional","affiliation":[{"name":"Service de Pneumophtisiologie, H\u00f4pital National Ignace Deen, Universit\u00e9 Gamal Abdel Nasser de Conakry, Conakry, Guinea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia","family":"Belo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Funda\u00e7\u00e3o T\u00e9cnico Educacional Souza Marques, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria J","family":"Cook","sequence":"additional","affiliation":[{"name":"Provincial Tuberculosis Services, British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada"},{"name":"Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Schwartzman","sequence":"additional","affiliation":[{"name":"McGill International TB Centre, Montreal, Quebec, Canada"},{"name":"Department of Medicine, McGill University, Montreal, Quebec, Canada"},{"name":"Montreal Chest Institute, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anete","family":"Trajman","sequence":"additional","affiliation":[{"name":"Department of Medicine, McGill University, Montreal, Quebec, Canada"},{"name":"Department of Epidemiology, Social Medicine Institute, State University of Rio de Janeiro, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick","family":"Menzies","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada"},{"name":"McGill International TB Centre, Montreal, Quebec, Canada"},{"name":"Montreal Chest Institute, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,8,12]]},"reference":[{"key":"2021110300070362100_CIT0001","volume-title":"WHO end TB strategy","year":"2014"},{"key":"2021110300070362100_CIT0002","volume-title":"Latent tuberculosis infection: updated and consolidated guidelines for programmatic management","year":"2018"},{"key":"2021110300070362100_CIT0003","volume-title":"Canadian tuberculosis standards: 7th edition","author":"Public Health Agency of Canada","year":"2014"},{"key":"2021110300070362100_CIT0004","volume-title":"Tuberculosis: guidance and guidelines","author":"National Institute for Health and Care Excellence","year":"2016"},{"key":"2021110300070362100_CIT0005","volume-title":"CDNA national guidelines for public health units\u2014management of TB","author":"Australian Government Department of Health","year":"2015"},{"key":"2021110300070362100_CIT0006","first-page":"1","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection","volume":"49","author":"American Thoracic Society","year":"2000","journal-title":"MMWR Recomm Rep"},{"key":"2021110300070362100_CIT0007","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/M17-0609","article-title":"Treatment of latent tuberculosis infection: an updated network meta-analysis","volume":"167","author":"Zenner","year":"2017","journal-title":"Ann Intern Med"},{"key":"2021110300070362100_CIT0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020","volume":"69","author":"Sterling","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"2021110300070362100_CIT0009","doi-asserted-by":"crossref","first-page":"m549","DOI":"10.1136\/bmj.m549","article-title":"Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"2021110300070362100_CIT0010","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(19)30575-4","article-title":"Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials","volume":"20","author":"Campbell","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2021110300070362100_CIT0011","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa1714283","article-title":"Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults","volume":"379","author":"Menzies","year":"2018","journal-title":"N Engl J Med"},{"key":"2021110300070362100_CIT0012","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/0003-4819-149-10-200811180-00003","article-title":"Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial","volume":"149","author":"Menzies","year":"2008","journal-title":"Ann Intern Med"},{"key":"2021110300070362100_CIT0013","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: hepatotoxicity of antituberculosis therapy","volume":"174","author":"Saukkonen","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2021110300070362100_CIT0014","author":"National Cancer Institute","year":"2009"},{"key":"2021110300070362100_CIT0015","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"2021110300070362100_CIT0016","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/aje\/kwf215","article-title":"Statistical analysis of correlated data using generalized estimating equations: an orientation","volume":"157","author":"Hanley","year":"2003","journal-title":"Am J Epidemiol"},{"key":"2021110300070362100_CIT0017","author":"SAS Institute"},{"key":"2021110300070362100_CIT0018","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1164\/rccm.200404-478OC","article-title":"Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months","volume":"170","author":"Menzies","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"2021110300070362100_CIT0019","first-page":"1","article-title":"The R package geepack for generalized estimating equations","volume":"15","author":"H\u00f8jsgaard","year":"2005","journal-title":"J Stat Softw"},{"key":"2021110300070362100_CIT0020","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02048-2019","article-title":"Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion, and costs","author":"Ronald","year":"2020","journal-title":"Eur Respir J"},{"key":"2021110300070362100_CIT0021","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/archinte.162.9.985","article-title":"Rifampin and rifabutin drug interactions: an update","volume":"162","author":"Finch","year":"2002","journal-title":"Arch Intern Med"},{"key":"2021110300070362100_CIT0022","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1001\/archinte.144.8.1667","article-title":"Rifampin drug interactions","volume":"144","author":"Baciewicz","year":"1984","journal-title":"Arch Intern Med"},{"key":"2021110300070362100_CIT0023","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/FTD.0000000000000108","article-title":"Pharmacological interactions between rifampicin and antiretroviral drugs: challenges and research priorities for resource-limited settings","volume":"37","author":"Semvua","year":"2015","journal-title":"Ther Drug Monit"},{"key":"2021110300070362100_CIT0024","volume-title":"Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV","year":"2018"},{"key":"2021110300070362100_CIT0025","first-page":"549","article-title":"Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: a multicenter, noncomparative, open-label, randomized trial","volume":"70","author":"Dooley","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021110300070362100_CIT0026","doi-asserted-by":"crossref","first-page":"6366","DOI":"10.1128\/AAC.01124-13","article-title":"Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine","volume":"57","author":"Williamson","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2021110300070362100_CIT0027","first-page":"991","article-title":"Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study","volume":"117","author":"Kopanoff","year":"1978","journal-title":"Am Rev Respir Dis"},{"key":"2021110300070362100_CIT0028","volume-title":"Prover som ing\u00e5r i en h\u00e4lsounders\u00f6kning","author":"Stockholm","year":"2019"},{"key":"2021110300070362100_CIT0029","volume-title":"Management of latent tuberculosis in adults: guideline","author":"Queensland Health","year":"2016"},{"key":"2021110300070362100_CIT0030","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/S0149-2918(99)80026-5","article-title":"Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice","volume":"21","author":"Farmer","year":"1999","journal-title":"Clin Ther"},{"key":"2021110300070362100_CIT0031","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/ckj\/sfz072","article-title":"Is polypharmacy an increasing burden in chronic kidney disease? The German experience","volume":"12","author":"Parker","year":"2019","journal-title":"Clin Kidney J"},{"key":"2021110300070362100_CIT0032","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/COH.0000000000000608","article-title":"Polypharmacy in HIV: recent insights and future directions","volume":"15","author":"Edelman","year":"2020","journal-title":"Curr Opin HIV AIDS"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa1169\/33804985\/ciaa1169.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/9\/e3545\/41059372\/ciaa1169.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/9\/e3545\/41059372\/ciaa1169.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T20:08:25Z","timestamp":1635883705000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/9\/e3545\/5891810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,12]]},"references-count":32,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,8,12]]},"published-print":{"date-parts":[[2021,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa1169","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2020,8,12]]}}}